EP4

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023

Retrieved on: 
Friday, November 10, 2023

Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023.
  • Lean, go-to-market commercial model, well positioned to scale rapidly to generate significant value from Japan and APAC (ex-China) geographic expansion.
  • Note regarding the Idorsia transaction: the quarter ended 30 September 2023 (Q3 2023) is the first period in which the Group has consolidated the financial results of Idorsia’s former Japanese and South Korean businesses.
  • Revenue totalled JPY 5,474 million (US$39.6 million*), a decrease of JPY 3,167 million (US$27.9 million) vs. the prior corresponding period.

EQS-News: Environmental and Social Impact Assessment completed for Phase One ZERO CARBON LITHIUM™ Project

Retrieved on: 
Thursday, December 14, 2023

Vulcan Energy Resources Limited (Vulcan, ASX: VUL, FSE: VUL, the Company) announces that its Environmental and Social Impact Assessment (ESIA) for Phase One of its Zero Carbon Lithium™ Project (Project) has been completed by ERM.

Key Points: 
  • Vulcan Energy Resources Limited (Vulcan, ASX: VUL, FSE: VUL, the Company) announces that its Environmental and Social Impact Assessment (ESIA) for Phase One of its Zero Carbon Lithium™ Project (Project) has been completed by ERM.
  • Vulcan is advancing Phase One of its ZERO CARBON LITHIUM™ Project: the first integrated project delivering renewable energy and lithium, from Europe for Europe.
  • Key outcomes of the ESIA report:
    The environmental and social baseline, impact assessment, and cumulative impact assessment completed by ERM is in line with lenders’ requirements to ensure a level of environmental performance prior to the furnishing of debt finance, e.g.
  • Vulcan’s ESG Lead, Storm Taylor, commented: “The completion of the Environmental and Social Impact Assessment marks a significant milestone in the advancement of our Zero Carbon Lithium™ Project.

Mesentech Doses First Patients with Investigational Drug MES1022 to Accelerate Healing of Bone Fractures

Retrieved on: 
Tuesday, September 26, 2023

Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.

Key Points: 
  • Efficient drug delivery into bones remains a barrier in developing treatments for diseases of bone.
  • The bone is a complex, dynamic tissue with unique properties that make it a formidable challenge for drug efficient penetration.
  • The company successfully dosed the first patients via subcutaneous injection in a Phase 1 study evaluating MES1022, a bone-selective EP4 receptor agonist prodrug they are developing for bone regeneration, with the first application for accelerating healing of bone fractures.
  • “MES1022 is well-positioned to be the first therapy that mimics and enhances the natural processes the body uses to stimulate bone repair and healing.

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Retrieved on: 
Thursday, August 10, 2023

HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).

Key Points: 
  • HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4).
  • In cancer, PGE2 acts in the tumor microenvironment to trigger cancer cells to evade the immune system.
  • Phase IIa of the trial will expand the optimal combination dose in up to four cohorts in specified cancer indications.
  • Sosei Heptares holds a license to the results generated under the trial to continue the clinical development and commercialization of HTL0039732.

Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company

Retrieved on: 
Thursday, July 20, 2023

This fully funded transaction is truly transformational and achieves one of our key strategic objectives, establishing the Company as a fully integrated Japan-focused biopharmaceutical business, with growing commercial sales and an expected new product launch next year.

Key Points: 
  • This fully funded transaction is truly transformational and achieves one of our key strategic objectives, establishing the Company as a fully integrated Japan-focused biopharmaceutical business, with growing commercial sales and an expected new product launch next year.
  • “The Japan pharmaceutical market, given its size, large ageing population and attractive high quality clinical development and regulatory environment is the key next step for Sosei Heptares’ growth ambitions.
  • I would also like to welcome Dr. Satoshi Tanaka and the other members of the IPJ and IPK teams to Sosei Heptares.
  • The acquisition of IPJ and IPK addresses this objective and is the conclusion of a rigorous global search by the Sosei Heptares team.

Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together

Retrieved on: 
Wednesday, July 19, 2023

BRISBANE, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that in vivo and in vitro data on the unique mechanism of TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling, were published in Cancer Research Communications, a journal of the American Association for Cancer Research.

Key Points: 
  • BRISBANE, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that in vivo and in vitro data on the unique mechanism of TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling, were published in Cancer Research Communications, a journal of the American Association for Cancer Research.
  • “While the biology of PGE2 in promoting tumor growth and immune suppression is well established, there are still no approved drugs for cancer that effectively block the prostaglandin pathway,” said Tom Dubensky, Ph.D., president of Tempest.
  • “Our innovation with TPST-1495 shows for the first time the effect of blocking PGE2 signaling through the EP2 and EP4 pro-tumor receptors while maintaining the important anti-tumor signaling of PGE2 through the EP1 and EP3 receptors, which could be an important advance to inhibiting PGE2.
  • Additionally, these results further support what we believe is an innovative and robust pipeline at Tempest that includes TPST-1120, a novel PPAR⍺ antagonist, which has shown early positive data from an ongoing global randomized study in first-line HCC patients.”

Park Systems Appoints Stefan Schneider as General Manager of Accurion Division

Retrieved on: 
Monday, July 10, 2023

SEOUL, South Korea, July 10, 2023 /PRNewswire/ -- Park Systems , a leading provider of Atomic Force Microscopy (AFM) and nano-metrology solutions, is pleased to announce Stefan Schneider as the new General Manager of Park Systems Accurion Division (Park Systems GmbH), a prominent provider of imaging spectroscopic ellipsometry (ISE) and active vibration isolation (AVI) systems.

Key Points: 
  • SEOUL, South Korea, July 10, 2023 /PRNewswire/ -- Park Systems , a leading provider of Atomic Force Microscopy (AFM) and nano-metrology solutions, is pleased to announce Stefan Schneider as the new General Manager of Park Systems Accurion Division (Park Systems GmbH), a prominent provider of imaging spectroscopic ellipsometry (ISE) and active vibration isolation (AVI) systems.
  • "We are excited to announce Stefan Schneider as the new General Manager of Accurion, Park Systems.
  • We look forward to working closely with Stefan and the Accurion team to deliver innovative solutions to our customers worldwide," Dr. Sang-il Park, CEO of Park Systems Corporation said.
  • Additionally, Accurion's AVI systems will allow Park Systems to meet its own demand for vibration isolation and expand its customer base.

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities

Retrieved on: 
Monday, June 5, 2023

Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.

Key Points: 
  • Through this precision research strategy, backed by two decades of deep-expertise in understanding GPCRs, the Company has developed a novel series of potent and selective PAR2 NAMs.
  • PAR2 is a novel therapeutic target in oncology and immuno-oncology, involved in several processes such as tumor proliferation, resistance to immunotherapy and fibrosis.
  • Domain nominated DT-9045 as a first-in-class PAR2 NAM clinical candidate based on its added-value, unique properties and greater therapeutic potential in comparison to biologics targeting PAR2 currently in the clinic by several competitors.
  • Dr. Pascal Neuville, CEO of Domain Therapeutics, commented: “The nomination of our first-in-class PAR2 NAM drug candidate, DT-9045, is an exciting step forward for Domain Therapeutics and for cancer treatment in general.

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 22, 2023

“2022 featured significant milestones for the company, including our first clinical proof of concept data, which was recognized in an oral presentation at ASCO,” said Stephen Brady, chief executive officer of Tempest.

Key Points: 
  • “2022 featured significant milestones for the company, including our first clinical proof of concept data, which was recognized in an oral presentation at ASCO,” said Stephen Brady, chief executive officer of Tempest.
  • TREX1 Inhibitor (preclinical tumor-selective STING pathway activator): presented the first preclinical anti-tumor results with proprietary small molecule TREX1 inhibitor at AACR 2022.
  • Tempest ended the year with $31.2 million in cash and cash equivalents, compared to $51.8 million on December 31, 2021.
  • Based on current cash position and operating plan, Tempest expects to have sufficient resources to fund operations through the second quarter of 2024.